Abstract

Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed.We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials.A total of 33.9, 34.3, and 31.8% patients were aged <65 years, =65 to <75 years, and =75 years, respectively. Age <65 years was associated with less favorable International Prognostic Scoring System (IPSS) risk and additional cytopenias at baseline versus older age groups, significantly lower cytogenetic response rates (p?=?0.022 vs. =65 to <75 years; p?=?0.047 vs. =75 years), and higher rates of acute myeloid leukemia (AML) progression (Gray's test, p?=?0.013). Lenalidomide was equally well tolerated across age groups, producing consistently high rates of red blood cell transfusion independence =26 weeks.Baseline disease characteristics and AML progression appear to be more severe in younger lower-risk MDS patients with del(5q), whereas older age does not seem to compromise the response to lenalidomide.ClinicalTrials.gov NCT00065156 and NCT00179621.

View details for DOI 10.1186/s13045-017-0491-2

View details for Web of Science ID 000404058800001

View details for PubMedID 28651604

View details for PubMedCentralID PMC5485496